Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.
Read Original Story

Nicotine patches, gum don’t prevent relapse, study finds

Rating

3 Star

Nicotine patches, gum don’t prevent relapse, study finds

Our Review Summary

It fell short by failing to tap any independent sources for commentary and perspective on the findings, by failing to compare the nicotine products to any alternatives for smoking cessation and by relying too heavily on a drugmaker’s press release.

 

Why This Matters

Smoking continues to be a hugely destructive force in public health, even after decades of anti-smoking campaigns and mountains of studies documenting the damage. With dwindling resources for public health efforts, any study that can help policymakers better focus their resources could be a boon in the short and long term.

Criteria

Does the story adequately discuss the costs of the intervention?

Satisfactory

The story addresses the broad scope of costs: “American smokers spend more than $1.5 billion on nicotine gum, patches and related products each year, according to the study. Much of that comes from public health programs, which are facing further rounds of budget cuts.”

We would have liked to see actual costs for some of these products and a comparison to cigarettes. People might be more likely to continue buying nicotine products if they are cheaper than the cigarettes themselves.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Satisfactory

This story and the New York Times story both failed to mention the actual number of people in the study who used nicotine products. Instead, it talked about the overall number of study participants and then provided percentages for the people who relapsed, perhaps leaving readers confused about whether and to what extent nicotine products made a difference in smoking cessation. It says, “The new study examined former smokers three times over a five-year period. At the midpoint of the study, 30.6% of recent quitters had gone back to smoking. By the end, 31.3% had relapsed.” It isn’t clear whether we are talking about the same 30% in each period or a total of roughly 60%.

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

No mention of the potential harms from taking nicotine, as opposed to quitting without drug therapy. There’s also the question of whether people are doing themselves more harm by continuing to smoke because they failed to quit with the help of a nicotine replacement product. If they had been able to more effectively quit earlier, would they live longer?

Does the story seem to grasp the quality of the evidence?

Not Satisfactory

The story, like the others we reviewed, provides the basic outlines of the study design. It does not do a very good job pointing out any potential limitations with the research. It relies on one of the biggest makers of nicotine products — GlaxoSmithKline — as the sole voice criticizing the study. Unlike the New York Times story, this one did not place the study into context. The story notes:   “The findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s. In those trials, volunteers using such products were up to three times more likely to kick the smoking habit.” The NYT did a better job by adding a proviso:  “In medical studies the products have proved effective, making it easier for people to quit, at least in the short term.”

But it’s also important to note:  the FDA approved nicotine replacement therapy for smoking cessation and only looked at short term outcomes (6 months to a year).  Recidivism is a critical issue for any addiction including smoking.  So it isn’t entirely accurate to report that “the findings run counter to the results of trials conducted before the FDA gave the thumbs up.”

Does the story commit disease-mongering?

Satisfactory

No disease mongering.

Does the story use independent sources and identify conflicts of interest?

Not Satisfactory

This story quoted no independent experts. The only comments it used that were not from the lead researcher were from GlaxoSmithKline. “But GlaxoSmithKline Consumer Healthcare, which makes Nicorette, Nicoderm, Commit lozenges and other smoking cessation products, said that would be premature. The company noted that most of the adults in the study who used nicotine replacement products didn’t use them for the recommended eight weeks. Had those people followed directions, they might have had more success.” This idea appears to have been refuted in the study itself, which showed that the duration that people took the products did not seem to make a difference. A better criticism might have been that it is difficult to tell how these people truly complied with the product because they were not being actively monitored in a clinical trial but were only responding to survey questions.

Does the story compare the new approach with existing alternatives?

Not Satisfactory

There is no comparison to alternatives in this story.

Does the story establish the availability of the treatment/test/product/procedure?

Satisfactory

The story basically used sales information to indicate availability. We did appreciate that this story mentioned a wide variety of nicotine products, including nasal sprays.

Does the story establish the true novelty of the approach?

Not Applicable

There were no claims of novelty in the story.

Does the story appear to rely solely or largely on a news release?

Not Satisfactory

The story did not rely on this press release from Harvard, but it did rely on this press release from GlaxoSmithKline, one of the big makers of nicotine replacement products. The dependence on the company’s release for the sole outside perspective on the study casts a cloud over a story that already leaves too many questions unanswered. Fully 25% of the words in the story were turned over to the Glaxo response.

 

 

Total Score: 4 of 9 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.